Impact of infusion method on amikacin serum levels in humans.
Simon
N
N
Biopharmacy, Galenic and Hospital Pharmacy Department EA 4034, Lille Nord de France University, France.
Décaudin
B
B
Lannoy
D
D
Odou
M F
MF
De Broucker
M
M
Barthélémy
C
C
Poret
E
E
Dubreuil
L
L
Odou
P
P
D000368:Aged; D000369:Aged, 80 and over; D000583:Amikacin / Q000008:administration & dosage / Q000493:pharmacokinetics*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D001424:Bacterial Infections / Q000188:drug therapy*; D017714:Community-Acquired Infections / Q000188:drug therapy*; D005260:Female; D006207:Half-Life; D006801:Humans; D007260:Infusion Pumps; D007262:Infusions, Intravenous; D008171:Lung Diseases / Q000188:drug therapy / Q000382:microbiology; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D014018:Tissue Distribution
D000900:Anti-Bacterial Agents; D000583:Amikacin